NICE backs liraglutide for diabetes

NICE has approved the GLP-1 analogue liraglutide for the treatment of some type-2 diabetes patients.

In draft guidelines issued today, liraglutide 1.2 mg daily has been recommended in combination with metformin or a sulphonylurea for patients intolerant or unsuitable for add-on therapy with metformin, a sulphonylurea, a thiazolidinediones and a dipeptidyl peptidase-4 inhibitor.

As part of triple therapy regimens, liraglutide 1.2mg daily is recommended only when control of blood glucose is inadequate, patients have a BMI over 35 or are unsuitable for insulin therapy.

The institute has recommended liraglutide 1.2mg, but not the 1.8mg dose. It said that available evidence did not suggest any significant additional benefit with the higher dose.

Final NICE guidance on liraglutide is likely to be published in October 2010.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus